Keyword: Eli Lilly

The FDA has handed Lilly’s Emgality a 'breakthrough' nod in cluster headaches. Lilly plans to file for approval in that use by the end of the year.

Johnson & Johnson's Janssen is using Twitter to get the word out about the link between Type 2 diabetes and cardiovascular risks.

With outcomes data showing Farxiga lowers hospitalizations for heart failure or CV deaths against placebo, AZ plans to file for a new FDA label.

Generic competition is weighing on Cialis, but luckily for Lilly, several new drugs are on the upswing, including top performers Trulicity and Taltz.

All eyes are on Eli Lilly’s Trulicity as it faces down new competition. But the drugmaker just notched an important trial win that shows it can hang with its rival.

Is Pfizer’s Lyrica leaving the TV ad game? Facing patent expiration, the stalwart top 10 TV spender dropped its budget to $3.8 million in October.

Novo will reduce headcount by 1,300 by the end of 2018 to feed resources into its drug launches and marketing, as well as R&D.

It’s been more than a year since J&J showed Invokana could improve heart safety, but the company's reps can finally tout those benefits.

Novo Nordisk rolled out more data for its next great hope: oral semaglutide, which would be the only pill in a hotly competitive GLP-1 class.

A pile of evidence for CDK 4/6 cancer drugs hasn’t yet persuaded some physicians to try the meds, but Pfizer's going all out to change their minds.